Pheno Therapeutics secures two patents for neurological disease drug pipeline

Pheno Therapeutics has secured two patents protecting its GPR17 antagonist programmes, including its lead multiple sclerosis candidate and a second drug targeting amyotrophic lateral sclerosis.

The UK biotechnology company said the patents cover a crystalline form of PTD802 and the composition of matter of PTD939, strengthening intellectual property protection across its neurological disease pipeline.

Patent GB2642355 covers a polymorph, or crystalline form, of PTD802. The company said this provides additional protection for the specific form of its lead candidate being developed for clinical use, alongside existing patents licensed from UCB that cover the compound itself in multiple countries.

The second patent, GB2700773, covers the composition of matter of PTD939, Pheno’s second GPR17 antagonist programme. The company described this as its strongest form of intellectual property protection for the asset, which is entering IND-enabling studies with an initial focus on amyotrophic lateral sclerosis (ALS).

Both candidates target GPR17, a G protein-coupled receptor that Pheno is investigating as a potential therapeutic target in neurological and neurodegenerative diseases.

PTD802 cleared for clinical development

PTD802 is a small molecule designed to promote remyelination, the process through which the protective myelin sheath surrounding nerve fibres is restored.

Pheno is initially developing the candidate for multiple sclerosis (MS), a disease in which damage to myelin disrupts communication between the brain and the rest of the body.

The candidate has received clinical trial authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA).

These regulatory clearances allow the company to proceed with clinical studies in both countries. Pheno said PTD802 is the first GPR17 programme to receive IND clearance.

The planned first-in-human study is expected to begin in the fourth quarter of 2026 and will assess safety and tolerability in healthy volunteers. No clinical efficacy data have yet been reported.

Fraser Murray, CEO of Pheno Therapeutics, said: “We are building a strong, layered IP position around GPR17 with two protected assets, one of which is already cleared for clinical study in the UK and US. The chemistry and development work carried out by the Pheno team has been instrumental in the success of these patent applications, which will now go on to support the long-term value of the pipeline. We look forward to providing further updates as we progress PTD802 to a first-in-human trial.”

PTD939 adds an ALS programme

The second asset, PTD939, is also a selective GPR17 antagonist. Pheno is advancing it towards IND-enabling studies, initially for ALS, a progressive neurodegenerative disease affecting nerve cells responsible for controlling voluntary muscles.

The composition-of-matter patent protects the compound itself, rather than a particular formulation or crystalline form. This is an important distinction from the additional patent protection secured for PTD802.

The company has not disclosed a clinical trial start date for PTD939. Its development remains at an earlier stage than PTD802, which has already received regulatory clearance to enter human studies.

Building protection around GPR17

The patents add to Pheno’s existing intellectual property position, including worldwide exclusive licensing rights from UCB covering PTD802.

The patent applications were based on earlier priority filings, followed by international Patent Cooperation Treaty applications. These include WO2026/008995 for the PTD802 polymorph and WO2025/243046 for PTD939 compounds. National or regional filings are being prepared in several territories.

The two programmes give Pheno a pipeline focused on GPR17 antagonism across different neurological indications, with PTD802 approaching first-in-human evaluation and PTD939 progressing through preclinical development.

Mail Icon

news via inbox

Sign up for our newsletter and get the latest news right in your inbox